# COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival

> **NCT07729241** · — · COMPLETED · sponsor: **Groupe Hospitalier Pitie-Salpetriere** · enrollment: 95015 (actual)

## Conditions studied

- Cancer
- Immune Checkpoint Inhibitors
- COVID-19 Vaccination
- Survival

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07729241
- **Lead sponsor:** Groupe Hospitalier Pitie-Salpetriere
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-28
- **Primary completion:** 2024-12-31
- **Final completion:** 2026-09-10
- **Target enrollment:** 95015 (ACTUAL)
- **Last updated:** 2026-09-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729241, "COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07729241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*